Pembrolizumab plus radiation before surgery for rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving pembrolizumab (an immunotherapy medicine) together with short-course radiation before surgery helps people with localized rectal cancer. It is mainly for tumors that are microsatellite stable (MSS).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older, and your rectal cancer was confirmed by biopsy.
- Your cancer is localized rectal adenocarcinoma (not spread to distant organs), in a specific TNM stage group.
- Your tumor is microsatellite stable (MSS), not MSI-high.
- Your overall health is good enough for treatment (ECOG 0–1).
- A tumor board recommends short-course radiation plus surgery before treatment begins.
- You can provide tumor tissue that has not had radiation before (archived block or a fresh biopsy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving chemotherapy and an immunotherapy drug before surgery can help shrink rectal cancer tumors and improve outcomes. It is for patients whose tumors are not caused by a specific genetic mismatch repair problem.
This trial tests a combination of short-course radiation, chemotherapy, and two types of immunotherapy (HLX07 and Serplulimab) before surgery for advanced rectal cancer. It aims to see if this approach helps shrink tumors and improve outcomes.
This trial tests a combination of immunotherapy (tislelizumab) and standard chemotherapy and radiation before surgery for low rectal cancer. The goal is to help shrink or eliminate the tumor so surgery might be less invasive or not needed, allowing you to keep your rectum.
This trial tests a combination of a PD-L1 inhibitor (adebrelimab), short-course radiation, and chemotherapy given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
Hear when a new Rectum Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.